| Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo J Beegle, K Lakatos, S Kalomoiris, H Stewart, RR Isseroff, JA Nolta, ... Stem cells 33 (6), 1818-1828, 2015 | 230 | 2015 |
| Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors T Meyerrose, S Olson, S Pontow, S Kalomoiris, Y Jung, G Annett, G Bauer, ... Advanced drug delivery reviews 62 (12), 1167-1174, 2010 | 203 | 2010 |
| Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy FA Fierro, S Kalomoiris, CS Sondergaard, JA Nolta Stem cells 29 (11), 1727-1737, 2011 | 174 | 2011 |
| Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington's disease mouse models K Pollock, H Dahlenburg, H Nelson, KD Fink, W Cary, K Hendrix, G Annett, ... Molecular Therapy 24 (5), 965-977, 2016 | 168 | 2016 |
| Concise review: MicroRNA function in multipotent mesenchymal stromal cells EA Clark, S Kalomoiris, JA Nolta, FA Fierro Stem cells 32 (5), 1074-1082, 2014 | 154 | 2014 |
| Characterization and In Vivo Testing of Mesenchymal Stem Cells Derived from Human Embryonic Stem Cells W Gruenloh, A Kambal, C Sondergaard, J McGee, C Nacey, S Kalomoiris, ... Tissue engineering Part A 17 (11-12), 1517-1525, 2011 | 126 | 2011 |
| Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin SD Olson, A Kambal, K Pollock, GM Mitchell, H Stewart, S Kalomoiris, ... Molecular and Cellular Neuroscience 49 (3), 271-281, 2012 | 99 | 2012 |
| Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell–derived induced pluripotent stem cells A Kambal, G Mitchell, W Cary, W Gruenloh, Y Jung, S Kalomoiris, ... Molecular Therapy 19 (3), 584-593, 2011 | 89 | 2011 |
| Preclinical evaluation of mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia JR Beegle, NL Magner, S Kalomoiris, A Harding, P Zhou, C Nacey, ... Molecular therapy Methods & clinical development 3, 2016 | 70 | 2016 |
| Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human huntington's disease fibroblasts KD Fink, P Deng, J Gutierrez, JS Anderson, A Torrest, A Komarla, ... Cell transplantation 25 (4), 677-686, 2016 | 61 | 2016 |
| FGF2 induces migration of human bone marrow stromal cells by increasing core fucosylations on N-glycans of integrins B Awan, D Turkov, C Schumacher, A Jacobo, A McEnerney, A Ramsey, ... Stem cell reports 11 (2), 325-333, 2018 | 40 | 2018 |
| Fibroblast Growth Factor 2 Regulates High Mobility Group A2 Expression in Human Bone Marrow‐Derived Mesenchymal Stem Cells S Kalomoiris, AC Cicchetto, K Lakatos, JA Nolta, FA Fierro Journal of cellular biochemistry 117 (9), 2128-2137, 2016 | 31 | 2016 |
| Mesenchymal stem cells respond to hypoxia by increasing diacylglycerols K Lakatos, S Kalomoiris, B Merkely, JA Nolta, FA Fierro Journal of cellular biochemistry 117 (2), 300-307, 2016 | 22 | 2016 |
| CD25 preselective anti-HIV vectors for improved HIV gene therapy S Kalomoiris, JT Lawson, RX Chen, G Bauer, JA Nolta, JS Anderson Human gene therapy methods 23 (6), 366-375, 2012 | 12 | 2012 |
| Genetic monitoring and effects of stocking practices on small Cyprinus carpio populations N Karaiskou, M Lappa, S Kalomoiris, G Oikonomidis, C Psaltopoulou, ... Conservation genetics 12, 1299-1311, 2011 | 5 | 2011 |
| Mesenchymal stem cells as a delivery vehicle for intercellular delivery of RNAi to treat Huntington's disease GA Mitchell, SD Olson, KM Pollock, A Kambal, WA Cary, K Pepper, ... NEUROLOGY 76 (9), A541-A541, 2011 | 2 | 2011 |
| Huntington's Disease Mouse Models K Pollock, H Dahlenburg, H Nelson, KD Fink, W Cary, K Hendrix, G Annett, ... Molecular Therapy 24 (5), 965-977, 2016 | 1 | 2016 |
| Mesenchymal stem cells engineered to overexpress brain-derived neurotrophic factor as a proposed therapeutic for Huntington’s disease (S25. 007) V Wheelock, K Pollock, H Dahlenberg, H Nelson, K Fink, W Cary, ... Neurology 86 (16_supplement), S25. 007, 2016 | 1 | 2016 |
| 32. Safety studies towards a combined cell and gene therapy to treat critical limb ischemia JR Beegle, S Kalomoiris, NL Magner, JA Nolta, FA Fierro Molecular Therapy 23, S14, 2015 | 1 | 2015 |
| Role of MiRNAs and HMGA2 in Human Mesenchymal Stem Cells S Kalomoiris University of California, Davis, 2016 | | 2016 |
Jan NoltaProfessor, Director of the Stem Cell Program, University of California DavisZweryfikowany adres z ucdavis.edu
